UNIVERSITY PARK, Pennsylvania, Sept. 14 -- Pennsylvania State University posted the following news: * * * Cancer-linked protein binds to chromosome in unexpected way, study finds * UNIVERSITY PARK, Pa. -A new 3D-structure of a cancer-linked protein bound to its cellular partner reveals details of how the protein binds to chromosomes and could offer insights for future disease treatments. The protein -BRD4 -plays a critical role in how cells read, copy and repair DNA and helps determine how different kinds of cells are made; it has been link more PR

AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC * (SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely more PR

AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Extended-Interval Tarlatamab Dosing Shows Consistent Activity and Safety in Previously Treated Small Cell Lung Cancer * (SEOUL, Republic of Korea -Saturday, September 12th, 6:15 p.m. Korea Standard Time) - Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety, and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with  more PR

AURORA, Colorado, Sept. 14 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * IASLC Tumor Budding Grade Identifies High-Risk Patients With Resected Lung Squamous Cell Carcinoma * (SEOUL, Republic of Korea -Tuesday, September 15th, 9:45 a.m. Korea Standard Time) -A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher ris more PR

AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC * (SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -Results from the Phase III PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numer more PR

AURORA, Colorado, Sept. 14 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Investigational Immunotherapy Nearly Doubles Overall Survival Compared with Docetaxel in Advanced Squamous NSCLC * (SEOUL, Republic of Korea -Tuesday, September 15th, 9:45 a.m. Korea Standard Time) -Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the inves more PR

RARITAN, New Jersey, Sept. 15 -- Johnson and Johnson Innovative Medicine issued the following news release: * * * Johnson & Johnson's RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, more PR

AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Late-Breaking HARMONi-2 Analysis Shows Ivonescimab Significantly Improves Overall Survival Versus Pembrolizumab in PD-L1-Positive Advanced NSCLC * (SEOUL, Republic of Korea -September 13th at 10:45 a.m. Korea Standard Time) -Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung canc more PR

AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Local Consolidative Therapy Does Not Improve Survival After Dual Immunotherapy in Metastatic NSCLC * (SEOUL, Republic of Korea -Saturday, September 12th, 6:15 p.m. Korea Standard Time) - Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung c more PR

AURORA, Colorado, Sept. 14 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Mobile CT Lung Cancer Screening Expands Access for Underserved Populations in Brazil * (SEOUL, Republic of Korea -Tuesday, September 15th, 9:45 a.m. Korea Standard Time) -Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) more PR

ITHACA, New York, Sept. 14 -- Cornell University College of Veterinary Medicine posted the following news: * * * New path for old protein may present additional therapies for rare genetic disease * A new study from scientists at the Cornell University College of Veterinary Medicine has revealed interesting insights that can help with new therapeutic approaches for a rare genetic disease Cystinosis is uncommon but serious causing an amino acid called cystine to build up in cells, eventually causing kidney failure. The condition is caused by more PR

AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Perioperative Atezolizumab Plus Chemotherapy More Than Doubles Event-Free Survival in Resectable Stage II-IIIB NSCLC * (SEOUL, Republic of Korea -Saturday, September 12th 6:15 p.m. Standard Time) -Patients with resectable stage IIB-IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 mo more PR

AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC * (SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) - First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patien more PR

BASEL, Switzerland, Sept. 15 (TNSxrep) -- Roche, a biotech company, issued the following news release: * * * Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer * Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% more PR

RESTON, Virginia, Sept. 14 [Category: Medical] -- The Society of Nuclear Medicine and Molecular Imaging issued the following news release: * * * What's Next for Theranostics? * Theranostics is now a mature cancer treatment modality, and The Journal of Nuclear Medicine (JNM) is capturing the moment in a new supplement: "Theranostics: The State of the Art." Guest edited by Ken Herrmann, MD, MBA, with JNM Editor-in-Chief Johannes Czernin, MD, the supplement brings together top voices in the field to map out where theranostics stands today and  more PR

AURORA, Colorado, Sept. 14 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Study Identifies Distinct Outcomes and Genomic Features in NSCLC With Class II and III BRAF Alterations * (SEOUL, Republic of Korea -Tuesday, September 15th, 9:45 a.m. Korea Standard Time) -Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentia more PR

STORRS, Connecticut, Sept. 14 -- The University of Connecticut posted the following news: * * * The Connecticut National Medical Association Society Hosts Black Doctors Day at UConn Health * The Connecticut National Medical Association Society (CTNMA) hosted Black Doctors Day for students across the state interested in pursuing medical careers on August 29, 2026. The goal of the event was to give students the opportunity to meet physicians who look like them, while learning more about career options in a variety of medical fields directly  more PR

AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release: * * * Zidesamtinib Demonstrates 93% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC * (SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previo more PR